Wolverine Trading’s Acceleron Pharma XLRN Stock Holding History

Wolverine Trading’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,606	Closed	-$200K	–	7349
2021 Q2	$200K	Buy	+1,606	New	+$203K	﹤0.01%	5026
2020 Q1	–	Sell	-13,821	Closed	-$727K	–	5583
2019 Q4	$727K	Buy	+13,821	New	+$630K	﹤0.01%	2720
2018 Q4	–	Sell	-17,747	Closed	-$1.02M	–	5672
2018 Q3	$1.02M	Buy	+17,747	New	+$872K	﹤0.01%	2346

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Wolverine Trading's XLRN Position: Q3 2021 in Review

Wolverine Trading sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 1,606 shares — an estimated $200K sold.

Wolverine Trading first reported a position in XLRN in Q3 2018 and held it in 3 quarters. The position peaked at $1.02M in Q3 2018. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

Wolverine Trading reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
Wolverine Trading sold 1,606 Acceleron Pharma shares in Q3 2021, an estimated $200K.
Wolverine Trading first reported a position in Acceleron Pharma in Q3 2018 and held it in 3 quarters.
Wolverine Trading's Acceleron Pharma position peaked at $1.02M in Q3 2018.
330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Wolverine Trading's 13F filing for Q3 2021, filed 12 Nov 2021.